The prognostic significance of phosphatase and tensin homolog loss in breast cancer

0Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.
Get full text

Abstract

AIM: This study aims to determine the prognostic significance of phosphatase and tensin homolog (PTEN) loss in breast cancer. METHODS: We conducted a meta-analysis study. Sample of this study were research articles that evaluated PTEN loss and prognosis in breast cancer patients. We searched for relevant studies published in PubMed and Proquest from January 2010 to July 2018. We reviewed studies that examined the association between immunohistochemical expression of PTEN and breast cancer prognosis using meta-analysis methods. Pooled risk ratios (RR) were calculated using fixed and random-effect models. Data were processed using Review Manager 5.3 (RevMan 5.3). RESULTS: There were 7 studies conducted a systematic review then continued to evaluate the association of PTEN loss and breast cancer prognosis by meta-analysis. There was a significant association of PTEN loss with poor prognosis of breast cancer (RR = 0.76 [95% CI 0.59-0.98 p <0.07), and there was not any significant publication bias for studies included. CONCLUSION: This study confirmed PTEN loss is an important independent factor for breast cancer prognosis.

Cite

CITATION STYLE

APA

Windarti, I., Harahap, W. A., Nindrea, R. D., Yerizel, E., & Rustamadji, P. (2019). The prognostic significance of phosphatase and tensin homolog loss in breast cancer. Open Access Macedonian Journal of Medical Sciences. Open Access Macedonian Journal of Medical Sciences. https://doi.org/10.3889/oamjms.2019.757

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free